NCT06555939 Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
| NCT ID | NCT06555939 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-10-23 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2025-10-23 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a resilience-promoting intervention through a Collaborative Care Model. The primary goal is to determine with the resilience intervention (PRISM) is feasible and acceptable for adolescents and young adults with SCD. Exploratory outcomes include whether this intervention improves depression, anxiety, and pain interference.
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 8 and ≤ 25 years of age at baseline * Diagnosed with Sickle Cell Disease (HbSS, HbSC, HbS-Beta Thalassemia, and other related hemoglobinopathies) * Receiving Medical Care at the DFCI/BCH Blood Disorders Center. * Scored \> 9 on Patient Health Questionnaire 9-item (PHQ-9) or Generalized Anxiety Disorder (GAD) * Able to speak English or Spanish language (for PRISM sessions) * Able to read English or Spanish language (for completion of surveys) * Cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator * Willing and able to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: \* does not meet above criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06555939 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 25 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06555939 currently recruiting?
Yes, NCT06555939 is actively recruiting participants. Contact the research team at abbyr_rosenberg@dfci.harvard.edu for enrollment information.
Where is the NCT06555939 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06555939 clinical trial?
NCT06555939 is sponsored by Boston Children's Hospital. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.